November 2012 last close over $1.56

The highest ever close was on 1 May 2012 at $1.835 it jumped around a bit on the heady Phase lll cure trial for Vivagel before its last close at $1.62 on 27 November 2012 before the crash after the results were judged inconclusive.

So what has changed?

The Phase lll BV cure result has now been reversed to a success as a result of FDA changes to the conditions.

The Phase lll BV prevention trial has been successful.

We have government approvals in ANZ and Europe for OTC Vivagel.

We are well advanced on the FDA process.

We have completed a Phase l and started a trial of an improved version of Docetaxel, the major chemotherapy agent for a number of cancers. This drug will be the one you will most likely treated with for metastatic prostate and other cancers in Australia.

We have completed pre-clinical trials with fabulous results for two other major first line chemotherapy drugs, Cabazitaxel and Irinetocan, and are about to start clinical trials.

We have $50M in the bank.

We have three major Pharmaceutical companies trialling our technology with signs of success.

So beyond $3 in a short space of time would seem to be inevitable.